<DrugInformationSummary id="CDR0000777063"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>This page contains brief information about daratumumab
         and a collection of links to more information about the use of 
         this drug, research results, and ongoing clinical trials.
  </DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/daratumumab">Daratumumab</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000583564">daratumumab</TerminologyLink><GlossaryLink ref="CDR0000776992">daratumumab</GlossaryLink><USBrandNames><USBrandName>Darzalex</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>DAYR-uh-TOOM-yoo-mab</TermPronunciation><MediaLink ref="CDR0000778389" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000778388" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4d0efe9-5e54-467e-9eb4-56fa7d53b60b&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Daratumumab</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4d0efe9-5e54-467e-9eb4-56fa7d53b60b&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">Daratumumab
         is approved to be used alone or with other drugs to treat:</Para>                          
  <ItemizedList Style="bullet" id="_3">
   <ListItem><Strong><GlossaryTermRef href="CDR0000045793" dictionary="Cancer.gov" audience="Patient">Multiple myeloma</GlossaryTermRef>.</Strong> It is used: <ItemizedList Style="bullet" id="_8"><ListItem>In adults with newly diagnosed disease. It is used:<ItemizedList Style="bullet" id="_6"><ListItem>With <GlossaryTermRef href="CDR0000393761" dictionary="Cancer.gov" audience="Patient">lenalidomide</GlossaryTermRef> and <GlossaryTermRef href="CDR0000045262" dictionary="Cancer.gov" audience="Patient">dexamethasone</GlossaryTermRef> or with <GlossaryTermRef href="CDR0000269133" dictionary="Cancer.gov" audience="Patient">bortezomib</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045957" dictionary="Cancer.gov" audience="Patient">melphalan</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000045492" dictionary="Cancer.gov" audience="Patient">prednisone</GlossaryTermRef> in patients who cannot receive an <GlossaryTermRef href="CDR0000270733" dictionary="Cancer.gov" audience="Patient">autologous stem cell transplant</GlossaryTermRef>.</ListItem><ListItem>With bortezomib, <GlossaryTermRef href="CDR0000045458" dictionary="Cancer.gov" audience="Patient">thalidomide</GlossaryTermRef>, and dexamethasone in patients who can receive an autologous stem cell transplant.</ListItem></ItemizedList></ListItem><ListItem>In adults with <GlossaryTermRef href="CDR0000045866" dictionary="Cancer.gov" audience="Patient">relapsed</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045863" dictionary="Cancer.gov" audience="Patient">refractory</GlossaryTermRef> disease. It is used:<ItemizedList Style="bullet" id="_7"><ListItem>With dexamethasone and bortezomib in patients who have  received at least one therapy.</ListItem><ListItem>With dexamethasone and <GlossaryTermRef href="CDR0000737706" dictionary="Cancer.gov" audience="Patient">carfilzomib</GlossaryTermRef> in patients who have  received one to three other types of therapy.</ListItem>  <ListItem>With <GlossaryTermRef href="CDR0000589401" dictionary="Cancer.gov" audience="Patient">pomalidomide</GlossaryTermRef> and dexamethasone in patients who have received at least two therapies that included lenalidomide and a <GlossaryTermRef href="CDR0000393541" dictionary="Cancer.gov" audience="Patient">proteasome inhibitor</GlossaryTermRef>.</ListItem><ListItem>Alone in patients who have received at least three types of therapy that included a proteasome inhibitor  and an <GlossaryTermRef href="CDR0000739791" dictionary="Cancer.gov" audience="Patient">immunomodulating agent</GlossaryTermRef> or whose disease is refractory to both  a proteasome inhibitor and an immunomodulatory agent.</ListItem></ItemizedList> 

</ListItem></ItemizedList></ListItem>
   
   </ItemizedList>
  <Para id="_9">Daratumumab is also available in a different form, combined with <GlossaryTermRef href="CDR0000791166" dictionary="Cancer.gov" audience="Patient">hyaluronidase</GlossaryTermRef>. For more information, see the Drug Information Summary for <DrugRef href="CDR0000801597" url="/about-cancer/treatment/drugs/daratumumabandhyaluronidase-fihj">Daratumumab and hyaluronidase-fihj</DrugRef>.</Para><Para id="_4">Daratumumab
         is also being studied in the treatment of other types of
         cancer.</Para>
 </Section><Section id="_About"><Title>More About Daratumumab</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/583564">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.52">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a616002.html">Daratumumab</ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.53"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.54">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2025/fda-daratumumab-isatuximab-newly-diagnosed-myeloma">FDA Approvals Expand Initial Treatment Options for Multiple Myeloma</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2024/multiple-myeloma-darzalex-plus-vrd">Trial Results Support Adding Daratumumab to Initial Treatment for Multiple Myeloma</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Therapy to Treat Cancer</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies">Monoclonal Antibodies</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C74007">Find Clinical Trials for Daratumumab</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2015-11-25</DateFirstPublished><DateLastModified>2025-01-07</DateLastModified></DrugInformationSummary>
